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WHICH USEFUL TOXICOLOGICAL INFORMATION CAN BE DRAWN 
FROM STUDIES ON THE HEPATIC FIXATION OF ANTICOAGULANT 
RODENTICIDES 
J.C. LECHEVIN and A. VIGIE, Centre de recherche LIPHA, 115 avenue Lacassagne, 69003 Lyon, France 
ABSTRACT: Anticoagulant rodenticides act at the hepatic level where they are more or less fixed according to their 
lipophilic nature. The studies on kinetics and metabolism carried out with no toxic doses are useful to know how products act 
but do not allow to anticipate the toxicity risks for non target species, because of low residual contents. These risks can only be 
assessed after the administration of toxic doses taking into account the residue levels. The use of half-life to express the results 
is not sufficiently accurate and may lead to wrong conclusions. The studies involving the residue and secondary toxicity levels 
are more accurate for assessing the risks. Some examples are given in particular for bromadiolone. 
Proc. 15th Vertebrate Pest Conf. (J. E. Borrecco & R. E. Marsh, 
Editors) Published at University of Calif., Davis. 1992 
INTRODUCTION 
Anticoagulant rodenticides exert their antivitamin K 
effect at the hepatic level by preventing the transformation 
of vitamin K epoxide into reduced vitamin K. Coagulation 
factors depending on vitamin K being no longer activated, 
blood coagulation does not work properly and induces the 
onset of internal haemorrhages (Figure 1, Meehan 1984). 
The hepatic fixation of anticoagulant rodenticides var-
ies in time according to products. It seems closely related to 
the lipophilic nature of the molecule and that explains the 
more potent activity of products called second generation 
products. Therefore, bromadiolone turns out to be more lipo-
philic than warfarin because of the length and structure of its 
side chain; presence of 2 phenyl rings and a bromine atom 
(Figure 2). 
The first data on the hepatic behaviour of products are 
given by the studies on kinetics and metabolism classically 
carried out on lab rodent strains which are given low but no 
lethal doses in order to keep animals in life as long as neces-
sary. These studies interesting for the knowledge of products 
are not adequate to surround the risk for non target species. 
Trials very similar to fight conditions must be added; lethal 
doses administered, where relevant to wild rodent strains. 
It is also classical to express the result of kinetic studies 
by calculating the half-lives and in particular the hepatic 
half-life. This way of calculating is not appropriate to the 
knowledge of risk for non target species and moreover var-
ies according to different factors. So, residue levels must 
be taken into account and toxicological consequences 
involved must be examined. These various points are going 
to be developed through some examples published in the 
literature. 
STUDIES ON KINETICS AND  
METABOLISM—RELATION BETWEEN 
RESIDUE LEVELS AND TOXICITY 
Several studies were dedicated to the kinetics and 
metabolism of flocoumafen in different species among which 
the rat (Huckle et al. 1989). The oral administration of a sub-
toxic dose: 0.14 mg/kg (LD50 0.25 mg/kg) of 14C flocou-
mafen shows that the behaviour of the product is the same as 
other anticoagulant rodenticides, in particular a preferential 
storage in the liver: about 50 percent of the administered 
dose. The hepatic concentration is about 1.2 µg/g of liver 
 
during the first 7 days and then slowly decreases and remains 
higher than 0.5 jag of liver 200 days after the administration. 
Assuming that the rats' liver of this experiment weighs 7 g on 
average, the maximum residual flocoumafen dose is 8.4 µg. 
This concentration may not have any toxic effect on non target 
species even on the most sensitive ones like the dog: LD50 
between 0.075 and 0.25 mg/kg (Johnson et al. 1986 mentioned 
in Lund 1988). In the worst case, LD50: 0.075 mg/kg corre-
sponds to a single absorption by a 10-kg dog of about 10 kg of 
poisoned rodents assuming that the liver contains 50 percent 
of the administered flocoumafen dose. This event is impos-
sible (Figure 3). 
Figure 2. Comparison of the structures of warfarin and broma-
diolone side chains emphasizing the more lipophilic nature of 
bromadiolone. 
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Figure 1. Simplified diagram of blood coagulation. 
Figure 4. Brodifacoum, bromadiolone: liver residues and tox-
icity for the dog (Brodifacoum - Godfrey et al. 1981, Bromadio-
lone - Poché 1988). 
The same conclusion may be drawn from the compara-
tive study of liver storage carried out with 4 anticoagulant 
rodenticides: brodifacoum, bromadiolone, coumatetralyl, and 
difenacoum 14C (Parmar et al. 1987). The authors indicate that 
the elimination of products from liver is biphasic, an initial, 
rapid phase lasting up to 8 days followed by a second very 
slower phase lasting up to several months depending on prod-
ucts. During the second phase, the concentrations for 
brodifacoum and bromadiolone for which the metabolism is 
low are 2-3 nmoles equivalent/g of liver, that is to say 1 to 1.6 
(µg/g. It is not specified in this summarized publication to 
which study time these values correspond to. If as previously 
seen, it is assumed that a rat's liver weighs 7 g, the total 
quantity of products: 7 to 11.2 µg may have no toxic conse-
quences for the dog, for instance when the single maximum 
tolerated doses by this species are taken into account (Figure 4). 
These 2 examples show very clearly that the studies on 
kinetics and metabolism carried out with no toxic doses give 
residue levels which do not allow to anticipate the toxicity 
risk for non target species. 
RESIDUE LEVELS AFTER ADMINISTRATION       
OF TOXIC DOSES 
The assay of anticoagulant rodenticide residues in ro-
dents poisoned with lethal doses, therefore under normal con-
ditions of struggle, is preferably made in the whole animal. 
For bromadiolone, in order to study the secondary toxic-
ity for stoat (Mustela erminea) and common buzzard (Bu-
teo buteo), water voles (Arvicola terrestris) were poisoned 
under different conditions and in particular under conditions 
similar to those of struggle: a 3-day carrot bait consumption 
titrated at 100 mg/kg of active ingredient (Grolleau et al. 
1989). After a 3-day bait consumption, the quantity of 
bromadiolone found in the whole animal is quite significant: 
10.93 mg/kg and then quickly decreases: 1.29 mg/kg in the 
following 2 days. Analyses made on rodents found killed 
after fields trial confirm the residue levels (Poche 1988). So, 
for a trial performed in Chino, California, the average re-
sidual content in bromadiolone was 1.92 mg/kg for the roof 
rat and 1.17 mg/kg for the mouse. These results are summa-
rized in Table 1. 
A similar quantity of residues (2.2 to 5.2 mg/kg) was 
found for voles (Microtus pinetorum) poisoned for 3 days 
with a bait titrated at 50 mg/kg of brodifacoum and then 
sacrificed on day 4 (Kaukeinen 1982). 
The administration of toxic doses gives low but quite 
significant residuary levels of brodifacoum and bromadiolone 
of about some ppm. In the kinetic study carried out with 
flocoumafen, assuming that 50 percent of the product is con-
centrated in the liver, the maximum residual concentration 
only represents a small proportion of ppm (0.07 mg/kg). 
STUDY ON KINETICS AND METABOLISM—
RESULTS EXPRESSED 
The elimination curve is an exponential and must be, for 
the calculation of half-life, drawn in a semi-logarithmic sys-
tem (log of concentrations). 
Choosing a mathematical model requires a lot of atten-
tion as shown by the following example from an unpublished 
study on liver storage with difethialone (Vigie 1989). The 
mathematical parameters calculated through the SIPHAR/PC 
software are summarized in Table 2. 
Although the correlation coefficient is slightly better in 
the model with 2 exponentials, the system with 1 exponential 
for which the relative standard deviations are the lowest ones 
must be chosen. This choice has some consequences on the 
half-life: 73 days (model with 1 exponential) instead of 159 
days (model with 2 exponentials, second half-life). 
The number of experimental points, therefore the study 
time may also act upon the value of half-life. So, in the previ-
ous trial, the 73-day value corresponding to a 6-month study 
is shortened to 51 days if the study is stopped 3 months after. 
Finally, the only half-life values taken into account may 
lead to wrong conclusions. So, in the study carried out by 
Parmar et al. (1987), it is mentioned that brodifacoum and 
bromadiolone have hepatic half-lives of 130 and 170 days 
respectively, which may make believe that the hepatic fixa-
tion of bromadiolone is higher. It is actually the contrary, as 
shown by a comparative study carried out on a lab rat strain 
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Table 1. Bromadiolone residues in different target species 
after the administration of toxic doses. 
Figure 3. Liver flocoumafen residues and toxicity for the dog.
Table 2. Study of liver storage of difethialone. R correlation 
coefficient between study time and deviations between re-
corded concentration and assessed concentration. 
Table 3. Secondary toxicity of bromadiolone. 
 
 
which was given a LD50 of each product (Ray et al. 1989). 
For the 3 rats administered 1.25 mg/kg of bromadiolone (dose 
slightly higher than LD50: 1.125 mg/kg) and sacrificed 5 days 
later, the hepatic content is lower than 0.06 µg/g of liver 
(detection limit). For brodifacoum (LD50 0.28 mg/kg), the 
contents 7 days after the administration are 0.4 and 2.2 µ/g 
of liver for 2 rats out of 3. It is therefore very clear that the 
value of half-life is not a sufficient accurate way for express-
ing results to allow to anticipate the secondary toxicity risk. 
Only the taking into account of residue levels allows it. 
RESIDUE LEVELS AFTER THE ADMINISTRA-
TION OF TOXIC DOSES—TOXICOLOGICAL 
CONSEQUENCES 
The studies measuring residues in association with the 
assay of secondary toxicity allow to precisely determine the 
toxicological consequences for non target species. Table 3 
summarizes some of the secondary toxicity results of 
bromadiolone for the buzzard and stoat in the study carried 
out by Grolleau et al. (1989). Mortality is only recorded in 
case of repeated administration of rodents. 
The absence of bromadiolone toxicity with a single in-
gestion of poisoned rodent was also noted for the fox, the 
supposed predator of the coypu (Morin 1988). We must be 
under severe experimental conditions - administration of coy-
pus poisoned by bromadiolone bait until death that is to say 
for 5 to 6 days - in order to record mortality. 
Other studies on secondary toxicity, without assaying 
residues in poisoned rodents, allowed to confirm the low 
toxicity of bromadiolone and to put forward differences be-
tween products. So, in the study on toxicity for the owl (Tyto 
alba) carried out by Mendenhall et al. (1980), the 6-day ad-
ministration of poisoned rodents by bromadiolone does not 
induce any sign of poisoning. Rodents must be given for 10 
days before noting the death of 1 bird out of 2. Under the 
same conditions, difenacoum which has a half-life similar to 
bromadiolone in classical kinetic studies (Parmar et al. 1987) 
induces haemorrhages without mortality after a 6-day admin-
istration. For brodifacoum, the mortality of the 2 birds is 
recorded after a 3-day administration of poisoned rodents. In 
the same way, the stone martens' consumption (Martesfoina) 
of 7 to 8 field mice a day during 4 days (total 31), poisoned 
during 4 days by a bromadiolone bait titrated at 50 mg/kg 
shows no consequence. Stone martens do not show any 
sign of poisoning (Lund et al. 1986). As a result, these 
experiments show that the toxicity risk for non target species 
is more significant in the case of repeated consumption of 
poisoned rodents. Different sensitivities must be noted among 
non target species. On another hand, products for which stud- 
ies on kinetics and metabolism may have made believed a 
similar toxicity have in fact quite different behaviours, very 
probably related to different residue levels. 
CONCLUSION 
It is important to make a clear difference of the useful-
ness of studies on kinetics in target rodents according to the 
administered dose. Low but no lethal doses are used to know 
absorption, distribution and elimination of products. They 
cannot be used to foresee the risk for non target species; the 
residuary contents represented by traces having no toxico-
logical meaning. In order to know the risk for non target 
species, residuary contents in poisoned rodents by lethal doses 
must be known. Only the values of the first days of intoxica-
tion are important from a toxicological point of view. 
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